Business
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"MAIA Biotechnology, Inc.","displaySize":"","headline":null,"caption":"MAIA Biotechnology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VsKDoji6rq9.7IotAdlg.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483","width":300,"height":114}},"lazy":false},{"type":"text","content":"Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells ","length":102,"tagName":"p"},{"type":"text","content":"CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled “Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,” was invented by MAIA’s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD.","length":734,"tagName":"p"},{"type":"text","content":"“Mercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the structure and function of telomeres and reduce immune system activity, interfering with the growth of cancer cells and causing programmed cancer cell death. As an important extension of MAIA’s innovative cancer treatment platform, these new compounds are key next-generation telomere-targeting agents with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity,” said Dr. Gryaznov.","length":555,"tagName":"p"},{"type":"text","content":"“The new IP is expected to further secure and expand the value of our first-in-class telomere-targeting compounds across the European scientific community,” added MAIA Chairman and CEO Vlad Vitoc, M.D.","length":201,"tagName":"p"},{"type":"text","content":"MAIA’s g...